VHT:ARCA-Vanguard Health Care ETF - DNQ

ETF | Others | NYSE Arca

Last Closing

USD 173.84

Change

+0.37 (+0.21)%

Market Cap

USD 5.43B

Volume

0.14M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks to track the performance of a benchmark index. The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the Global Industry Classification Standard (GICS). The Advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.

Inception Date: 26/01/2004

Primary Benchmark: MSCI US IMI/Health Care 25-50 GR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.1%

Management Expense Ratio: 0.10 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Others

Symbol Name Mer Price(Change) Market Cap
SOJE SOJE 0.00 %

+0.04 (+0.21%)

USD 65.72B
JEPI JPMorgan Equity Premium Income.. 0.00 %

-0.11 (-0.20%)

USD 32.78B
LCR Leuthold Core ETF 0.00 %

-0.09 (-0.27%)

USD 32.52B
DTB DTB 0.00 %

-0.12 (-0.63%)

USD 26.58B
DFAC Dimensional U.S. Core Equity 2.. 0.00 %

-0.03 (-0.10%)

USD 26.11B
JPST JPMorgan Ultra-Short Income ET.. 0.00 %

N/A

USD 22.47B
SGOV iShares® 0-3 Month Treasury B.. 0.00 %

+0.03 (+0.03%)

USD 18.58B
TSPA T. Rowe Price US Equity Resear.. 0.00 %

-0.07 (-0.22%)

USD 16.23B
DFUV Dimensional US Marketwide Valu.. 0.00 %

+0.04 (+0.10%)

USD 10.15B
AVUV Avantis® U.S. Small Cap Value.. 0.00 %

+0.02 (+0.02%)

USD 10.05B

ETFs Containing VHT

QLS 0.00 % 0.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.24% 37% F 36% F
Dividend Return 1.41% 66% D+ 45% F
Total Return 9.66% 38% F 36% F
Trailing 12 Months  
Capital Gain 4.16% 70% C- 65% D
Dividend Return 2.08% 56% F 40% F
Total Return 6.25% 70% C- 62% D
Trailing 5 Years  
Capital Gain 55.63% 89% A- 82% B
Dividend Return 10.08% 51% F 37% F
Total Return 65.71% 89% A- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 8.18% 71% C- 62% D
Dividend Return 9.68% 79% B- 61% D-
Total Return 1.50% 63% D 39% F
Risk Return Profile  
Volatility (Standard Deviation) 9.61% 71% C- 87% B+
Risk Adjusted Return 100.77% 86% B+ 93% A
Market Capitalization 5.43B 95% A 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.